An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia

An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia

There is a requirement for an efficacious vaccine to protect people against infection from Francisella tularensis, the etiological agent of tularemia. The lipopolysaccharide (LPS) of F. tularensis is suboptimally protective against a parenteral lethal challenge in mice. To develop a more efficacious...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura E. Marshall, Michelle Nelson, Carwyn H. Davies, Adam O. Whelan, Dominic C. Jenner, Madeleine G. Moule, Carmen Denman, Jon Cuccui, Timothy P. Atkins, Brendan W. Wren, Joann L. Prior
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2018/8087916
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items